Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement ...
RIM-TD open-label extension (OLE) study showed long-term improvement of Tardive Dyskinesia (TD) symptoms from treatment with deutetrabenazine over three years in European patients1 TD is an involuntary movement disorder that develops in around 15%-25% of …